Navigation Links
Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations
Date:12/7/2011

REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the relocation of its corporate headquarters and laboratory operations to 800 Saginaw Drive, Redwood City, California.

"Our move to a much larger and state-of-the art facility is a demonstration of our commitment to appropriately prepare for the growth and expansion expected with the launch of our first product," said Caren L. Mason, Chief Executive Officer of Verinata.  "We have designed a clinical laboratory with initial capacity of over 150,000 tests annually.  In addition, we have expanded our R&D laboratory substantially, with further expansion opportunities available for both clinical and research space. Our corporate headquarters is also designed to uniquely and distinctively support our physician, patient, and payer support teams to provide the education, training and support services for our laboratory developed test."

Ms. Mason continued, "We are pleased to report that our non-invasive prenatal test for multiple chromosomal abnormalities remains on track for commercial launch in the first quarter of 2012."

Verinata Health, Inc.

Verinata is driven by a sole, extraordinary purpose – maternal and fetal health.  Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies.  We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result.  Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011. For more information about Verinata, please go to www.verinata.com.

 


'/>"/>
SOURCE Verinata Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verinata Health Announces a Multi-Year Supply Agreement with Illumina in the Field of Non-Invasive Prenatal Diagnostics
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Tone Deafness Explained, from the Harvard Health Letter
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
(Date:2/24/2017)... 2017 Medivir AB (Nasdaq Stockholm: ... new Board of Directors that will be submitted to ... comprises representatives of the company,s three largest shareholders at ... have accepted a seat on the Nomination Committee, and ... 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provides business development, education, networking and recognition opportunities as well as advocacy for ... Works in Holmdel, NJ on February 23. The Council's Innovation Forecast event ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):